Aptevo Therapeutics Files 8-K
Ticker: APVO · Form: 8-K · Filed: Nov 26, 2024 · CIK: 1671584
| Field | Detail |
|---|---|
| Company | Aptevo Therapeutics Inc. (APVO) |
| Form Type | 8-K |
| Filed Date | Nov 26, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, regulatory-update
Related Tickers: APVO
TL;DR
APVO filed an 8-K, likely containing routine updates.
AI Summary
Aptevo Therapeutics Inc. filed an 8-K on November 26, 2024, to report other events and financial statements. The filing does not contain specific details about new events or financial figures within the provided text.
Why It Matters
This filing indicates that Aptevo Therapeutics Inc. is providing updates to the SEC, which could contain material information for investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and 'Financial Statements and Exhibits' without immediate disclosed material changes.
Key Players & Entities
- Aptevo Therapeutics Inc. (company) — Registrant
- November 26, 2024 (date) — Date of Report
- 206-838-0500 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing for Aptevo Therapeutics Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of November 26, 2024.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is November 26, 2024.
What is the principal executive office address for Aptevo Therapeutics Inc.?
The principal executive office address for Aptevo Therapeutics Inc. is 2401 4th Avenue Suite 1050, Seattle, Washington 98121.
What is the SEC file number for Aptevo Therapeutics Inc.?
The SEC file number for Aptevo Therapeutics Inc. is 001-37746.
What is the IRS Employer Identification Number for Aptevo Therapeutics Inc.?
The IRS Employer Identification Number for Aptevo Therapeutics Inc. is 81-1567056.
Filing Stats: 457 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-11-26 08:45:08
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value APVO The Nasdaq Stock Mar
Filing Documents
- apvo-20241126.htm (8-K) — 40KB
- apvo-ex99_1.htm (EX-99.1) — 20KB
- img237228349_0.jpg (GRAPHIC) — 4KB
- 0000950170-24-130763.txt ( ) — 187KB
- apvo-20241126.xsd (EX-101.SCH) — 25KB
- apvo-20241126_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On November 26, 2024, Aptevo Therapeutics Inc. ("Aptevo" or the "Company") issued a press release announcing Aptevo's Peter Pavlik, PhD, Senior Director of Protein Engineering, will chair a "Bi and Multispecific Biologics" session and present a talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR Platform," at the Cambridge Healthcare Institute's Pep Talk conference in January 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated November 26, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. APTEVO THERAPEUTICS INC. Date: November 26, 2024 By: /s/ Marvin L. White President and Chief Executive Officer